Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
medicare
4
×
national
4
×
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
immunotherapy
indiana blog main
indiana top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
autoimmune diseases
biogen
biotech ipos
bristol-myers squibb
cancer
cancer immunotherapy
cell therapy
crispr
deals
What
new
4
×
bio
roundup
companies
drug
ipo
market
remains
advantages
allogene
approval
arrival
bar
biogen’s
biopharmaceutical
biotech
brings
cancer
convo
crispr
days
diversity
earlier
expect
failures
gamble
hasn’t
hot
immunotherapy
industry
investors
ipos
juno
life
littered
medco’s
million
momentum
mover
nash
Language
unset
Current search:
national
×
new
×
medicare
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
